AOP Health unveiled new clinical results at the 67th ASH Annual Meeting in Orlando, highlighting two studies on ropeginterferon alfa-2b in myeloproliferative neoplasms to advance treatment strategies.

The presentations focused on ropeginterferon alfa-2b in essential thrombocythemia and polycythemia vera, underscoring its potential role in these conditions.

Ropeginterferon alfa-2b is the first interferon approved for polycythemia vera in the EU, delivered as a long-acting mono-pegylated formulation with a dosing schedule that starts biweekly and may extend to every four weeks after stabilization.

Background notes describe ropeginterferon alfa-2b as a proline-interferon with a long-acting, mono-pegylated profile and detail its regulatory status and administration.

In the EU, ropeginterferon alfa-2b is used as monotherapy for adults with polycythemia vera without symptomatic splenomegaly, administered via subcutaneous self-injection every two weeks, potentially extending to four weeks after stabilization.

The ROP-ET study is a prospective, multicenter, single-arm phase III trial evaluating ropeginterferon alfa-2b for essential thrombocythemia patients who cannot receive standard cytoreductive therapies, focusing on safety and efficacy.

CEO Martin Steinhart reiterates that AOP Health aims to share new findings with the scientific community to advance treatment strategies for chronic blood cancers.

ROP-ET targets patients with essential thrombocythemia lacking suitable conventional treatments, assessing ropeginterferon alfa-2b’s safety and efficacy in this difficult-to-treat group.

AOP Health emphasizes a commitment to addressing unmet patient needs in rare diseases through ongoing research and development, aligning with the ASH presentation.

The company highlights its Austrian roots, global reach, and philosophy—Need. Science. Trust.—as it focuses on rare diseases and intensive care medicine.

Context: AOP Health is a multinational group headquartered in Austria, working with subsidiaries and partners to advance research, physician collaboration, and patient advocacy in rare diseases.

The BESREMi-PASS study provides real-world evidence of ropeginterferon alfa-2b in polycythemia vera, offering practical insights into everyday clinical practice.

BESREMi-PASS analyzes ropeginterferon alfa-2b performance outside controlled trials, highlighting real-world treatment outcomes for polycythemia vera patients.